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Abstract.
Background: Rare variants in the low-density lipoprotein receptor related protein 10 gene (LRP10) have recently been
implicated in the etiology of Parkinson’s disease (PD) and dementia with Lewy bodies (DLB).
Objective: We searched for LRP10 variants in a new series of brain donors with dementia and Lewy pathology (LP) at
autopsy, or dementia and parkinsonism without LP but with various other neurodegenerative pathologies.
Methods: Sanger sequencing of LRP10 was performed in 233 donors collected by the Netherlands Brain Bank.
Results: Rare, possibly pathogenic heterozygous LRP10 variants were present in three patients: p.Gly453Ser in a patient
with mixed Alzheimer’s disease (AD)/Lewy body disease (LBD), p.Arg151Cys in a DLB patient, and p.Gly326Asp in an
AD patient without LP. All three patients had a positive family history for dementia or PD.
Conclusion: Rare LRP10 variants are present in some patients with dementia and different brain pathologies including DLB,
mixed AD/LBD, and AD. These findings suggest a role for LRP10 across a broad neurodegenerative spectrum.
Keywords: Genetic predisposition to disease, genotype, LRP10, neuropathology, phenotype
INTRODUCTION
Genetic factors play an important role in the eti-
ology of both Parkinson’s disease (PD) as well as
dementia with Lewy bodies (DLB) [1–3]. Among
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PD patients, 5–10% are estimated to carry disease-
causing rare mutations [3], including variants in
the SNCA gene, which are causal for PD as well
as DLB. Moreover, common variants in SNCA
and GBA are risk factors for both PD and DLB,
which further highlights the genetic overlap between
these disorders. Although mutations in more than
20 genes are known to cause monogenic forms of
PD, additional rare disease-associated genetic vari-
ants in familial PD and DLB likely remain to be
identified [1, 4].
ISSN 1387-2877/20/$35.00 © 2020 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0).
1162 L.J.M. Vergouw et al. / Phenotypes of LRP10 Variant Carriers with Dementia
We recently reported rare variants in the low-
density lipoprotein receptor related protein 10 gene
(LRP10) in familial forms of PD and DLB, including
one large Italian family with genome-wide significant
linkage evidence for late-onset, autosomal-dominant
inherited PD and DLB. All ten affected relatives and
three unaffected relatives (age 45–58 years) carried
the same rare LRP10 variant, suggesting an age-
related or incomplete penetrance. Several smaller
families showed additional, albeit more limited, evi-
dence of segregation of LRP10 variants with disease
[5]. In three probands with LRP10 variants, autopsy
studies showed diffuse-neocortical Lewy pathology
(LP) and concomitant AD-type pathology.
Since our initial report, additional rare LRP10 vari-
ants have been reported in patients with PD, DLB, or
other neurodegenerative diseases by some but not all
studies [6–13]. Three case-control studies searched
whole-exome sequencing data from sporadic PD,
DLB, and multiple system atrophy (MSA) cases,
and detected no evidence of association between rare
LRP10 variants and disease [6–8]. However, these
studies included mostly sporadic cases and controls
with a younger average age, and they might have been
underpowered to detect association due to the rarity
of pathogenic LRP10 variants, their likely incom-
plete penetrance, and the etiological heterogeneity
of these diseases. A French exome mining study
found a p.Tyr307Asn variant that co-segregated with
PD in two out of four members of the same family
[9]. Although the pathogenicity of this variant may
therefore be questioned, phenocopies are known to
occur in around 5% of familial PD patients from
families with monogenic forms of PD. Lastly, two
Chinese and one Dutch cohort studies of sporadic
and familial PD and DLB patients provided inde-
pendent, albeit limited, additional evidence for an
association of LRP10 variants with disease [11–13].
In addition, we recently found evidence for enrich-
ment of rare, possibly pathogenic LRP10 variants in a
large cohort of patients with progressive supranuclear
palsy (PSP), mostly with a pathologically confirmed
diagnosis [14]. In conclusion, despite some nega-
tive reports, additional evidence has been collected
on a role for rare LRP10 variants in independent
PD cohorts, and potentially other neurodegenera-
tive diseases such as PSP. However, confirmation in
independent large families as well as more exten-
sive functional evidence is needed. Moreover, the
findings of possibly pathogenic LRP10 variants in
other neurodegenerative diseases need confirmation
in pathologically-confirmed series.
Only few studies in the literature deal with the
normal function of LRP10 in the human brain.
LRP10 encodes transmembrane protein LRP10,
which shuttles between the plasma membrane and
the Golgi system and co-localizes with VPS35, a
retromer component and the product of another
known PD-causing gene [15–17]. LRP10 also inter-
acts with GGA proteins, which are reported to
affect -synuclein trafficking and aggregation [18,
19]. Furthermore, LRP10 has been implicated in
the metabolism of APOE lipoproteins and direct as
well as GGA-mediated regulation of APP traffick-
ing and processing, and may therefore also influence
amyloid- homeostasis [16, 20, 21]. Taken together,
this suggests a broad role for LRP10 in neurodegen-
eration.
The aim of this study was to search for LRP10
variants in a series of 233 brain donors from the
Netherlands Brain Bank (NBB), who were clinically
diagnosed with dementia, and had LP at autopsy or, if
LP-negative, had developed parkinsonism in addition
to dementia during their lifetime.
MATERIALS AND METHODS
Donor selection
The entire series of brains available from the NBB
(n = 3,853) from 1989 to 2017 was considered for
inclusion in the study according to the selection cri-
teria. For all donors, a written informed consent for
brain autopsy and the use of the material and clinical
information for research purposes had been obtained
from the donor or the next of kin.
For Group 1, inclusion criteria were: 1) Braak
Lewy body stage ≥4 according to the BrainNet
Europe (BNE) criteria [22]; 2) presence of dementia;
3) at least low levels of AD type pathology according
to National Institute on Aging–Alzheimer’s Asso-
ciation (NIA-AA) guidelines [23]. Out of all brain
donors from the NBB, 432 donors showed Braak
Lewy body stage ≥4, out of whom 324 showed
dementia. Of these donors, 252 showed at least low
levels AD type pathology. Some of these donors had
already been screened for LRP10 variants in a previ-
ous study [5], or did not have frozen tissue available
for DNA extraction, and were excluded. Therefore,
126 donors could be included in the current study.
For Group 2, inclusion criteria were: 1) presence
of dementia and parkinsonism; 2) presence of any
type of neurodegenerative disease upon autopsy; 3)
Braak Lewy body stage 0 or 1 according to the BNE
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criteria [22]. Parkinsonism was defined as bradyki-
nesia in combination with rigidity and/or tremor.
Donors with possible drug-induced parkinsonism
were excluded. Out of all brain donors from the NBB,
591 donors showed parkinsonism, of whom 543 had
sufficient information on cognitive status. Dementia
was present in 394 of these donors, of whom 182
did not show LP, and 148 did not take drugs that
could be a sufficient explanation for the presence
of parkinsonism. Seven cases had a known causal
genetic mutation. Out of the other 141 cases, tis-
sue was available for DNA extraction in 107 cases
that had not been screened before for the presence of
LRP10 variants.
Donors with known disease-causing mutations in
genes other than LRP10 were excluded. Fresh-frozen
brain tissue from cerebellum, cortical, or subcorti-
cal grey matter was available from 126 donors from
Group 1 and 107 donors from Group 2.
Clinical information
Clinical information was abstracted from the
database from the NBB and included information
on sex, age at onset, age at death, disease duration
from time at onset of first symptoms, presence and
timing of parkinsonism and dementia, a history of
parkinsonism or dementia in first-degree or second-
degree relatives, the clinical diagnosis by the treating
physician, and cause of death.
Neuropathological assessment
For all donors in the study selection, stan-
dardized neuropathological examinations had been
performed by an experienced neuropathologist
(AJMR) (open access: www.brainbank.nl). Neu-
ropathological assessment was done according to
NIA-AA and BNE guidelines [22, 23], and stan-
dardized evaluation strategies for cerebral amyloid
angiopathy (CAA) [24], granulovacuolar degenera-
tion [25], limbic-predominant age-related TDP-43
encephalopathy (LATE) [26], and aging-related tau
astrogliopathy (ARTAG) [27].
For the possibly pathogenic LRP10 variant carri-
ers, 17 different brain regions were formalin-fixed
and paraffin-embedded, cut into 8m sections, and
stained with hematoxylin and eosin. For selected cor-
tical regions, histological stainings were performed
using Congo red and Gallyas silver stains. Immuno-
histochemical analysis was performed on selected
brainstem, limbic, and neocortical regions using pri-
mary antibodies against -synuclein (clone KM51;
1 : 500; Monosan, The Netherlands), hyperphos-
phorylated tau (clone AT8; 1 : 1000; Innogenetics,
Belgium), amyloid- (clone 6F/3D; 1 : 100; Dako,
USA) and phospho-TDP43 (rabbit polyclonal;
1 : 1000 Cosmo Bio, USA). Stages of amyloid-
 plaques, neurofibrillary pathology, and neuritic
plaques were scored according to the NIA-AA guide-
lines [23], and stages of LP were scored according to
BNE criteria [22]. Standardized staging systems for
CAA [24], granulovacuolar degeneration [25], and
LATE [26] were applied. Presence of ARTAG was
evaluated based on tau immunostaining (clone AT8)
of sections of the hippocampus at the level of the lat-
eral geniculate nucleus, amygdala, and temporal pole
[27].
Sanger sequencing
Genomic DNA was isolated from brain tissue using
standard methods. We performed Sanger sequencing
using the reported protocol of Quadri et al. (2018) [5]
with minor modifications, for the entire open reading
frame and the exon-intron boundaries of LRP10. A
total volume of 20l, containing 2.0l of 10X Fast
Start Taq DNA Polymerase buffer, 1.6l of 2.5 mM
dNTPs, 1.0l of 10M forward primer, 1.0l of
10M reverse primer, 0.10 or 0.15l of FastStart
Taq. DNA Polymerase (Roche, Basel, Switzerland),
and 25 ng of genomic DNA, was used to amplify
the fragments. We added 4l of 1X GC-RICH solu-
tion (Roche) for exon 1, 5, and 7. An overview of
used primers can be found in Supplementary Table 1.
We performed the initial denaturation for 5 min at
94◦C followed by 30 cycles of 30 s at 94◦C, 30 s
at 60◦C, 90 s at 72◦C, with a final extension step
for 5 min at 72◦C. We used 5 units of ExoI and 0.5
unit of Fast AP (Thermo Fisher Scientific, Waltham,
MA, USA) for 45 min at 37◦C and 15 min at 80◦C
to remove unconsumed dNTPs and primers from
the PCR product (3l). The Big Dye Terminator
(version 3.1; Thermo Fisher Scientific) was used
according to the manufacturer’s protocol to sequence
both DNA strands directly and sephadexG50 (GE
Healthcare, Little Chalfont, UK) was used to remove
dye terminators. We used an ABI 3730XL Genetic
Analyzer (Thermo Fisher Scientific) and Seqscape
v3.0 (Thermo Fisher Scientific) for the analysis.
The LRP10 NM 0140445.4 transcript was used for
sequence variants annotation and the Human Genome
Variome Society recommendations [28] was used for
variants nomenclature.
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We considered variants as possibly pathogenic
according to the previously used criteria: 1) het-
erozygous state; 2) minor allele frequency <0.1%
in the genome aggregation database (GnomAD
v2.1); 3) exonic location and non-synonymous, or
predicted to affect splicing; and 4) predicted as
pathogenic by at least five of 11 in-silico programs
[5, 13].
Whole exome sequencing, copy number analysis,
and APOE genotyping
To exclude (possibly) pathogenic variants in other
known genes causing parkinsonism or dementia
(Supplementary Table 2) we performed whole exome
sequencing (WES) and multiple ligation-dependent
probe amplification (MLPA, P051-Parkinson mix 1)
in the possibly pathogenic LRP10 variant carriers.
WES was performed with the same protocol as previ-
ously reported in Jamra et al. (2017) [29]. An average
depth of >84× was reached, with 99% of the target
region covered >20×.
For copy number analysis, The P051-D1 Parkin-
son kit (MRC Holland) was used according to the
manufacturer’s protocol. An ABI 3730XL Genetic
Analyzer (Thermo Fisher Scientific) and Seqscape
v3.0 (Thermo Fisher Scientific) were used for
analysis. APOE genotyping was performed using
TaqMan® SNP Genotyping Assay (Thermo Fisher
Scientific).
RESULTS
Clinicopathological characteristics of the study
groups
Demographic, clinical, and neuropathological
information from the 233 selected donors are sum-
marized in Supplementary Tables 3 and 4. In Group
1, pathological diagnoses included PD with demen-
tia, DLB, AD with LP, mixed AD and Lewy
body disease (AD/LBD), frontotemporal demen-
tia (FTD) with LP, and PSP with LP. Distribution
of LP was amygdala-predominant (24%), limbic-
transitional (38%), or diffuse-neocortical (38%). In
Group 2, pathological diagnoses included AD, FTD,
vascular dementia, PSP, auto-immune encephalitis,
corticobasal degeneration, CRASH syndrome, mul-
tiple sclerosis, MSA, neurodegeneration with brain
iron accumulation, neuronal intranuclear inclusion
disease, and spinocerebellar ataxia. Among donors
with a specified clinical diagnosis, 77.5% was con-
firmed upon autopsy in Group 1 and 61.3% in
Group 2.
Genetic findings
Two donors (Patients 1 and 2) from Group 1 car-
ried each a different, possibly pathogenic LRP10
variant: c.1357G>A (p.Gly453Ser) and c.451C>T
(p.Arg151Cys) (mean allele frequency (MAF) Gno-
mAD 0.004% and 0.006%, respectively, predicted
as pathogenic in 5/11 and 9/11 in-silico pro-
grams respectively, Table 1 and Supplementary
Table 5). One donor (Patient 3) from Group 2 car-
ried a possibly pathogenic LRP10 variant: c.977G>A
(p.Gly326Asp) (MAF GnomAD 0.006%, predicted
as pathogenic in 6/11 in-silico programs, Table 1
and Supplementary Table 5). Additional LRP10 vari-
ants, which did not fulfill our criteria for possible
pathogenicity, are listed in Supplementary Tables 5
and 6. Additional WES and MLPA in possibly
pathogenic LRP10 variant carriers showed only one
possibly pathogenic variant, namely the ABCA7
p.Gly1741Arg variant in Patient 1 (Supplementary
Table 7). APOE genotypes of Patients 1, 2, and 3
were 3/4, 3/3, and 2/4 respectively.
Clinical phenotype of the LRP10 variant carriers
Patient 1, carrier of the p.Gly453Ser variant, was
clinically diagnosed with DLB. Throughout her life,
the patient suffered from recurrent depressions, anxi-
ety, and panic attacks. At the age of 64, she developed
severe constipation and a tremor of both hands, left
more than right, progressing into a hypokinetic-rigid
syndrome a year later. Her cognition rapidly deteri-
orated and neuropsychological examination showed
deficits in short term memory, difficulties with cal-
culations, visuoconstruction, and orientation. Brain
MRI showed mild general atrophy. Visual halluci-
nations, personality changes, and apraxia developed
during the course of the disease. The patient died at
the age of 72 due to pneumonia in an end-stage of
dementia. The father of the patient had been diag-
nosed with PD.
Patient 2, carrier of the p.Arg151Cys variant, was
clinically diagnosed with AD. She died at the age
of 90 due to cachexia and decubitus wounds, after
a disease duration of 10 years. The dementia was
characterized by memory loss, anxiety, visual hal-
lucinations, and delusions. Any other neurological
symptoms, in particular parkinsonism, were not men-
tioned in the clinical records. Her mother was also
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Table 2
Clinical and pathological characteristics of possibly pathogenic LRP10 variant carriers
Patient 1 Patient 2 Patient 3
LRP10 variant p.Gly453Ser p.Arg151Cys p.Gly326Asp
Sex F F M
Age at death y 72 90 88
Clinical diagnosis DLB AD AD
Age at onset y 64 80 77
Disease duration y 8 10 11
Dementia duration y 6 6 7
Parkinsonism yes not mentioned in clinical
records
yes
Family history father with PD mother with dementia brother and two aunts
with dementia
Cause of death pneumonia at end-stage
dementia
cachexia and pressure
ulcers at end-stage
dementia
pneumonia at end-stage
dementia
Neuropathological diagnosis mixed AD/LBD DLB AD
PMD h 5.5 5.5 5.0
APOE genotype 3/4 3/3 2/4
Brain weight g 1043 1053 1133
Atrophy moderate frontotemporal
and hippocampal
atrophy, severe dilation
of temporal horn of
lateral ventricle
none mild frontotemporal
atrophy, severe diffuse
dilation of ventricles
Pigmentation substantia nigra pale pale normal
Pigmentation locus coeruleus pale pale normal
Thal amyloid- phase [23] 5 3 5
Braak neurofibrillary stage [23] 6 4 4
CERAD score [23] C B B
AD-level [23] high intermediate intermediate
Braak Lewy body stage [22] 6 6 0
McKeith Lewy body stage [22] neocortical neocortical none
Microvascular lesions yes no yes
Hippocampal sclerosis no no no
Argyrophilic grain disease no no no
ARTAG [27] yes yes yes
CAA type 2 1 1
Thal CAA stage [24] 1 1 1
Granulovacuolar degeneration [25] yes, stage ≥ 4 yes, stage ≥ 4 yes, stage ≥ 4
Spongiform changes severe no mild
LATE [26] yes, stage 1 no no
DLB, dementia with Lewy bodies; AD, Alzheimer’s disease; PD, Parkinson’s disease; LBD, Lewy body disease; PMD, postmortem delay;
ARTAG, aging-related tau astrogliopathy; CAA, cerebral amyloid angiopathy; LATE, limbic-predominant age-related TDP43 encephalopa-
thy.
demented, but the clinical diagnosis of the mother is
not known.
Patient 3, carrier of the p.Gly326Asp variant, was
clinically diagnosed with AD. The patient had a dis-
ease duration of 11 years, starting with mild memory
disturbances. Seven years before death, neuropsy-
chological examination only showed mild short-term
memory problems, and walking became insecure. In
the following years, the patient developed parkin-
sonism, aphasia, frontal disinhibited behavior, and
anxiety. He died at the age of 88 due to pneumonia.
The brother and two aunts of the patient also suffered
from dementia (Table 2).
Pathological characteristics of the LRP10
variant carriers
Macroscopic examination of the brains of the three
possibly pathogenic LRP10 variant carriers showed
mild to moderate frontotemporal atrophy in Patients
1 and 3 (Table 2). Microscopy showed LP in brain-
stem, limbic, and neocortical brain areas in Patients 1
and 2 (Fig. 1. I–IIA, B), but no LP in Patient 3 (Fig. 1.
IIIA, B). Nigral degeneration was present in Patients
1 and 2. An intermediate or high level of AD-type
pathology was present in Patients 2 and 3, and Patient
1, respectively (Fig. 1. I–IIIC–E). All three patients
L.J.M. Vergouw et al. / Phenotypes of LRP10 Variant Carriers with Dementia 1167
showed ARTAG, as well as CAA, including capillary
CAA in Patients 2 and 3, and granulovacuolar degen-
eration in hippocampus and amygdala (Fig. 1. I–IIIF,
II–IIIG). Patient 1 showed LATE stage 1 (Fig. 1G).
The neuropathological diagnoses in the three patients
can be summarized as mixed AD/LBD, DLB, and
AD, respectively.
DISCUSSION
We found two possibly pathogenic LRP10 vari-
ants among 126 donors with dementia and LP, and
one among 107 donors with dementia and parkin-
sonism without LP. The first variant, p.Gly453Ser,
Fig. 1. (Continued).
was carried by a patient with clinically diagnosed
DLB and mixed AD/LBD upon autopsy. The second
variant, p.Arg151Cys, was carried by a patient clin-
ically diagnosed with AD, and a neuropathological
diagnosis of DLB. The third variant, p.Gly326Asp,
was carried by a patient with clinically diagnosed
AD plus parkinsonism, and pure AD pathology upon
autopsy. In the patient with the LRP10 p.Gly453Ser
variant, an additional rare variant (p.Gly1741Arg) in
ABCA7 was found. Rare disease-associated variants
in ABCA7 are considered risk factors for AD and PD
[30, 31], and therefore, the ABCA7 p.Gly1741Arg
variant may have contributed to the mixed AD/LBD
pathology in this patient, together with the LRP10
p.Gly453Ser variant.
While the three LRP10 variants are extremely rare
in control databases, they have all been reported
in independent studies in other patients with neu-
rodegenerative diseases. The p.Gly453Ser variant has
previously been found in a patient with clinically
diagnosed PD [6]. The p.Arg151Cys variant has pre-
viously been identified in a patient with PD with
dementia, who had a father with AD and gait prob-
lems [13]. This variant was also observed by us in
one out of 645 controls who were not neurologi-
cally examined [5]. Last, the p.Gly326Asp variant
has been previously reported in a pathologically con-
Fig. 1. Brain pathology in three patients with possibly pathogenic
LRP10 variants, with representative photomicrographs of selected
brain regions for Patient 1 (IA–G), Patient 2 (IIA–G), and Patient
3 (IIIA–G). Immunohistochemistry for -synuclein (clone KM51)
showed Lewy bodies and Lewy neurites in brainstem, limbic and
neocortical brain areas in Patients 1 and 2 (I–IIA, B), but no -
synuclein immunoreactivity in Patient 3 (IIIA, B). Diffuse and
cored amyloid- plaques (clone 6F/3D) were present in neocortical
regions, amygdala, and striatum in all three patients, and extended
into the CA4 region, midbrain, and cerebellum in Patients 1 and
3. Amyloid- positive plaques in the temporal pole are shown in
panel I–IIIC. Immunostaining for hyperphosphorylated tau (clone
AT8) showed neurofibrillary tangles, threads, and plaques in the
hippocampus and temporal pole in all three patients, and extended
into the peristriate and striate areas of the occipital cortex in Patient
1. A moderate or high load of neurofibrillary pathology was present
in the temporal pole in Patient 3 (IIID), and Patients 1 and 2
(I–IID), respectively. Gallyas silver stain showed a moderate or
high load of neuritic plaques in neocortical regions in Patients 2 and
3 (IIE, IIIE), and Patient 1(IE), respectively. Immunostaining for
phospho-TDP43 (polyclonal rabbit antibody) showed granulovac-
uolar degeneration in the hippocampus and amygdala of all three
patients (I–IIIF, II–IIIG). Additionally, Patient 1 showed TDP-43-
positive neuronal inclusions and threads in the amygdala fitting
limbic-predominant age-related TDP-43 encephalopathy (LATE;
IG). Scalebar in IIIE represents 50m and applies to panels A–E.
Scalebars in IIIF and IIIG represent 25m and apply to panels
I–IIIF-G. SN, substantia nigra, Temp cx, temporal pole.
1168 L.J.M. Vergouw et al. / Phenotypes of LRP10 Variant Carriers with Dementia
firmed MSA patient [8], and found by us in a patient
with clinically diagnosed PSP [14]. The lack of
pathological examination in some of the previously
reported patients complicates the overall interpreta-
tion of these findings.
We acknowledge that in some of these patients,
the LRP10 variant could have been a chance occur-
rence, with no roles in the disease development. Of
note, the identifiedLRP10 variants are all classified as
‘variants of uncertain significance’ by the American
College of Medical Genetics guidelines [32]. How-
ever, these guidelines are intended to guide genetic
testing in clinical practice, and therefore use strict
criteria for pathogenicity. Because of the exploratory
nature of the current study and the limited knowledge
in the literature on LRP10 mutations, we have used
less strict criteria to define pathogenicity. Although
more research is needed on the pathogenicity of
the described LRP10 variants, our results suggest a
pathogenic role for these LRP10 variants in a broad
spectrum of neurodegenerative disorders.
LRRK2 is a paradigmatic example of marked
pathological pleomorphism associated with
pathogenic variants in the same gene, even in
different members of the same family [33]. Simi-
larly, LRP10 variants may be related to a variety
of neuropathological lesions, including LP, AD
pathology, and possibly tauopathies. Especially
the association with AD pathology, next to LP,
is interesting as all three LRP10 variant carriers
reported in this study, as well as the three patients we
previously described [5], had an intermediate or high
level of AD pathology. Our detection of a possibly
pathogenic LRP10 variant in an AD case without LP
may suggest a role for LRP10 in the accumulation
of amyloid- or hyperphosphorylated tau. LRP10
is known to be involved in APP trafficking and
amyloid- homeostasis [16, 20], suggesting the
relevance of these pathways for the pathogenesis of
neurodegeneration in subjects with LRP10 variants.
This should be further investigated in future studies.
Of note, all three LRP10 variant carriers in this
study had one or more first- or second-degree rela-
tives with parkinsonism or dementia, as expected in
an autosomal-dominant inherited disease. Unfortu-
nately, the family of these brain donors could not be
contacted. As all patients died several years ago, their
house physicians at the time of death have unsuccess-
fully tried to contact living family members upon our
request. Therefore, a co-segregation analysis of the
LRP10 variants could not be performed, which is a
limitation of our study.
In conclusion, we observed possibly pathogenic
LRP10 variants in two patients with Lewy body
diseases, and in one with pure AD pathology. Further
studies of LRP10 in large, well-characterized cohorts
of patients with different types of neuropathology are
warranted.
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